NCT06224582已完成不适用
Efficacy and Safety of Yinxingmihuan Oral Solution in Treatment of Chest Pain After PCI: A Multicenter, Prospective, Randomized, Double-blind, Placebo-Controlled Study
China National Center for Cardiovascular Diseases1 个研究点 分布在 1 个国家目标入组 320 人开始时间: 2020年12月30日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 320
- 试验地点
- 1
- 主要终点
- SAQ-angina frequency
研究概览
简要总结
A prospective, multi-center, double-blind, randomized, placebo-controlled trial is conducted to evaluate the efficacy and safety of Yinxingmihuan oral solution in the treatment of chest pain after percutaneous coronary intervention (PCI) in patients with stable angina. Patients should undergo at least 1-week standardized medical treatment phase before randomization. The primary end point is the 12-week angina frequency assessed on the basis of Seattle Angina Questionnaire (SAQ) subscales. The main secondary endpoint is the improvement of anxiety assessed by Hamilton Anxiety Scale (HAMA) to evaluate its effectiveness for chest pain caused by psychological factors.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 85 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •male or female aged 18-85 years;
- •patients with a history of percutaneous coronary intervention for coronary heart disease for more than 30 days and less than 180 days, without need of further elective coronary revascularization (PCI, CABG) judged by cardiovascular specialists;
- •patients with symptoms such as chest distress, chest pain, palpitation, pain in shoulder and back, shortness of breath, weakness, activity intolerance, etc. Angina frequency (AF) score in Seattle Angina Questionnaire (SAQ) no more than 80;
- •Hamilton Anxiety Scale score between 7 and 21 (mild to moderate anxiety);
- •written informed consent.
排除标准
- •women who are pregnant or preparing to be pregnant or nursing, menstruating women;
- •women of child-bearing age who do not agree to use contraception during the medication phase;
- •patients with severe anxiety (Hamilton Anxiety Scale score more than 21);
- •patients with severe depression (Hamilton Depression Scale score not less than 24);
- •patients who are currently taking anti-anxiety drug;
- •participants with stable angina classified into Canadian Cardiovascular Society (CCS) Grade 4;
- •uncontrolled hypertension (systolic > 180 mmHg or diastolic > 100 mmHg) despite using ongoing antihypertensive treatment;
- •heart failure assessed by New York Heart Association (NYHA);
- •patients with coronary heart disease and atrial fibrillation;
- •clinically significant complications, including liver dysfunction (ALT or AST level more than 2 times higher than normal), renal dysfunction (serum creatinine level more than 2 times higher than normal), severe cardiopulmonary dysfunction, pulmonary hypertension, chronic obstructive pulmonary disease, history of cerebral hemorrhage or epilepsy, with need of anticonvulsant drugs;
- •within 7 days of introduction period, patients who no longer have angina-related symptoms;
- •within the three months before start of the study, patients with myocardial infarction or CCS 4 angina;
- •patients with acute coronary syndrome confirmed by examinations and other chest pain caused by rheumatic heart disease, dilated cardiomyopathy, severe neurosis, menopausal syndrome, hyperthyroidism, cervical spondylosis, bilio-cardiac syndrome, gastroesophageal reflux, hiatal hernia, aortic dissection, pulmonary embolism, mediastinal hematoma, etc;
- •history of specific bleeding or bleeding caused by warfarin;
- •patients with previous hematopoietic diseases;
- •patients who have undergone surgery (not including PCI) within the last 4 weeks and are prone to bleeding;
- •patients who participate in any other clinical study or take any other investigational drug within 90 days;
- •patients who are known or suspected to be allergic to the drug in this study or are allergic constitution;
- •drug abusers who have a history of alcohol abuse or drug dependence in the past 2 years;
- •psychopath;
- •patients who have been judged by their doctors to be ineligible for the study;
- •patient who is a family member or relative of the staff working in the centers.
研究组 & 干预措施
Yinxingmihuan group
Experimental
standardized medical treatment regimen plus Yinxingmihuan oral solution (oral, 10 ml once, 3 times a day)
干预措施: Yinxingmihuan oral solution (Drug)
Placebo group
Placebo Comparator
standardized medical treatment regimen plus Placebo oral solution (oral, 10 ml once, 3 times a day)
干预措施: Placebo (Drug)
结局指标
主要结局
SAQ-angina frequency
时间窗: at 12-week follow-up
angina frequency assessed on the basis of Seattle Angina Questionnaire (SAQ-AF)
次要结局
- HAMA improvement(at 12-week follow-up)
- NYHA class(before randomization, in 4,8,12,16 and 20 weeks)
- HAMA reductive ratio(at 12-week follow-up)
- weekly angina frequency(before randomization, in 4,8,12,16 and 20 weeks)
- SF-12 score(before randomization, in 4,8,12,16 and 20 weeks)
- Nitroglycerin discontinuation rate(before randomization, in 4,8,12,16 and 20 weeks)
- CCS grade(before randomization, in 4,8,12,16 and 20 weeks)
- VAS(before randomization, in 4,8,12,16 and 20 weeks)
- HAMD depression score(before randomization, in 4,8,12,16 and 20 weeks)
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
不适用
Clinical Trial of Jinzhen Oral Liquid in Treating Children With COVID-19 InfectionCOVID-19Child, OnlyNCT05507489The Affiliated Hospital of Qingdao University240
招募中
2 期
RCT for Yinqiaosan-Maxingganshitang in the Treatment of COVID-19COVID-19NCT05787327Chinese University of Hong Kong96
Unknown
3 期
Clinical Study of YYJD Decoction Combined With Gefitinib in Advanced Pulmonary AdenocarcinomaCancerNCT02929693Shanghai University of Traditional Chinese Medicine198
招募中
3 期
A Study of Comparing Overall Improvement of Patients With Spondyloarthritis Treated With Jitongning Tablets and PlaceboAnkylosing SpondylitisNCT06000956Tasly Pharmaceutical Group Co., Ltd408
招募中
4 期
Effect of Yangxinshi Tablet on Exercise Tolerance in Patients With Chronic Coronary Syndrome（MET STUDY）Chronic Coronary SyndromeNCT05978089Dongzhimen Hospital, Beijing120